摘要
目的探讨替尼泊甙(VM-26)为主的化疗方案相伴放疗治疗小细胞肺癌的临床疗效。方法53例小细胞肺癌中,48例选用VM-26+顺铂(DDP)方案,VM-26每天60mg/m2,DDP每天25mg/m2,连用3天为一个疗程;另5例用卡铂取代DDP,500mg静脉滴注,1天完成。除第1个与第2个疗程化疗间隔40天左右外,以后每4周重复1个疗程,共5个疗程。在第1个疗程化疗后1~4天内开始放射治疗。对局限期和广泛期患者分别照射不同的剂量和部位。结果局限期患者近期疗效为97.8%[完全缓解(CR)为53.3%,部分缓解(PR)为44.8%],1年和2年生存率分别为77.1%(27/35)和44%(11/25),中位生存期大于18个月。广泛期患者近期疗效为75%(CR25%),一年生存率为37.5%(3/8),中位生存期大于11个月。结论以VM-26为主的化疗方案相伴放疗是治疗小细胞肺癌的有效方案,可提高肿瘤的局部控制率。
PURPOSE To report the clinical results of teniposide (VM 26) combined with thoracic radiotherapy in the treatment of 53 cases of small cell lung cancer. METHODS Most cases were treated with VM 26+DDP,VM 26 60mg/m 2/d and DDP 25 mg/m 2/d, the consecutive treatment of 3 days was consideres as one course. Most patients were treated with 5 courses. Different radiation doses and radiation fields were performed for two clinical groups. RESULTS For the limited stage cases,the response rate reached 97 8% (CR53 5%, PR44 3%),and one and two years survival rates were 77 1% and 44% respectively. For the extensive stage cases,the response rates were 75% (CR25%,PR50%), and one and two years survival rates were 37 5% and 25% respectively. CONCLUSIONS The results indicated that teniposide combined with thoracic radiotherapy can be considered as an effective method for the treatment of small cell lung cancer.
出处
《中国癌症杂志》
CAS
CSCD
1997年第1期22-24,共3页
China Oncology
关键词
肺肿瘤
药物疗法
替尼泊甙
放射疗法
lung neoplasms
carcinoma,small cell
temiposide
drug therapy
radiotherapy